Photodynamic therapy in immune (non-oncological) disorders: Focus on benzoporphyrin derivatives

BioDrugs

Volumn 14, Issue 2, 2000, Pages 127-135

  Ratkay, Leslie G ^a   Waterfield, J Douglas ^b   Hunt, David W C ^a  

^a QLT Inc   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BENZOPORPHYRIN DERIVATIVE; CD18 ANTIGEN; CD86 ANTIGEN; COAL TAR; CYCLOSPORIN; CYTOKINE; HERMES ANTIGEN; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 10; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PSORALEN; QLT 0074; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; BINDING AFFINITY; CANCER INCIDENCE; CLINICAL TRIAL; CONTACT ALLERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PHOTOSENSITIZATION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SKIN GRAFT; TARGET CELL; TREATMENT INDICATION;

EID: 0033824476     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014020-00006     Document Type: Review

References (63)

1. Photodynamic therapeutics: Basic principles and clinical applications
2. Photodynamic therapy
3. Photodynamic therapy in oncology: Mechanisms and clinical use
4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report
5. Photodynamic therapy with verteporfin (Visudyne): Impact on ophthalmology and visual sciences
6. Non-oncologic potentials for photodynamic therapy
7. Immune modulation using transdermal photodynamic therapy
8. Immunomodulatory aspects of photodynamic therapy
9. Immunomodulatory aspects of photodynamic therapy
10. Pyrrolic photosensitizers
11. Preliminary studies on a more effective phototoxic agent than hematoporphyrin
12. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution
13. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo
14. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative
15. Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative
16. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives
17. Photosensitizers in photodynamic therapy
18. The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice
19. Activation of benzoporphyrin derivative in the circulation of mice without skin photosensitivity
20. Systemic photodynamic therapy is a safe and effective treatment of psoriasis
21. Porphyrin-mediated photosensitization - Taking the apoptosis fast lane
22. The photobiology of photodynamic therapy: Cellular targets and mechanisms
23. Photodynamic therapy: A mitochondrial inducer of apoptosis
24. Promotion of photodynamic therapy-induced apoptosis by stress kinases
25. Signal transduction through NF-kappa B
26. NF-κB: An important transcription factor in photobiology
27. NF-κB activation by the photochemotherapeutic agent verteporfin
28. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative
29. Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity
30. Oxidative stress as a mediator of apoptosis
31. Photodynamic therapy induces caspase-3 activation in HL-60 cells
32. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy
33. Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis
34. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
35. Apoptosis: The importance of being eaten
36. Photodynamic alteration of the surface receptor expression pattern of murine splenic dendritic cells
37. Dendritic cells and the control of immunity
38. Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis?
39. Modulation of cell surface adhesion and activation markers using low-dose photodynamic therapy
40. IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy
41. Evaluation of the immunotoxicity of benzoporphyrin derivative (BPD-MA) in mice
42. Photodynamic treatment of rheumatoid and inflammatory arthritis
43. A spontaneous rheumatoid arthritis-like disease in MRL/l mice
44. Complete Freund's adjuvant induces an earlier and more severe arthritis in MRL-lpr mice
45. Photodynamic therapy; a comparison with other immunomodulatory treatments of adjuvant-enhanced arthritis in MRL-lpr mice
46. Treatment of experimental murine arthritis with transdermal photodynamic therapy
47. Targeting activated lymphocytes with photodynamic therapy: Susceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitization
48. Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes
49. Uptake of verteporfin by articular tissues following systemic and intra-articular administration
50. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis
51. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy
52. Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative
53. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses
54. Transcutaneous photodynamic therapy alters the development of an adoptively transferred form of murine experimental autoimmune encephalomyelitis
55. Prolonged skin allograft survival after photodynamic therapy (PDT) associated with modification of donor skin antigenicity
56. Psoriatic arthritis: A unified concept twenty years on
57. The pathogenesis of psoriasis: Immunological facts and speculations
58. 312-Nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions
59. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy
60. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study
61. Photosensitizers for photodynamic immune modulation. Invited paper